Guggenheim Maintains Buy on Krystal Biotech, Raises Price Target to $175
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Krystal Biotech (KRYS) and raises the price target from $130 to $175.
February 27, 2024 | 5:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Debjit Chattopadhyay reaffirms a Buy rating on Krystal Biotech and increases the price target to $175.
The increase in price target by a reputable analyst like Debjit Chattopadhyay signals a strong confidence in Krystal Biotech's future performance. This is likely to positively influence investor sentiment and potentially lead to a short-term increase in KRYS's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100